



6 March 2025

ASX Announcement

RESULTS OF GENERAL MEETING

InhaleRx Ltd (ASX: IRX), ("**InhaleRx**", "**IRX**" 'or "**the Company**") an Australian healthcare company developing unique inhaled drug-device products to address unmet medical needs in the pain management and mental health sectors, advises a General Meeting (Meeting) was held today, 6 March 2025, commencing at 4pm AEDT.

The sole resolution put to members was voted on a poll. In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), details of the resolution, proxies received in respect of the resolution and poll results are set out in the attached summary.

The Board thanks shareholders for their support and looks forward to welcoming shareholders to its Town Hall webinar next Thursday, 13 March 2025, commencing at 4pm AEDT.

The webinar will be led by the Company's CEO, Darryl Davies, and Medical Advisor, Dr Sud Agarwal, who will provide an update on recent developments and the Company's progress in its clinical development program.

To access the webinar, please use the following link:

https://us02web.zoom.us/webinar/register/WN_tZuvU3iBT2eWAtvylCZhXA

Interested attendees are encouraged to email any specific questions they would like addressed by 5pm AEDT on Tuesday, 11 March 2025 to: info@inhalerx.com.au

Authorised by the Board of Directors.

For further information:

James Barrie Company Secretary

Phone +61 3 8678 4091

info@inhalerx.com.au www.inhalerx.com.au

About InhaleRx Limited (ASX: IRX) – www.inhalerx.com.au

InhaleRx Limited is an Australian healthcare company which is developing unique medicinal drug-device products to address unmet medical needs in pain management and mental health sectors.

The overarching goal is to pursue U.S. FDA approval and registration using rapid and cost-effective regulatory pathways, such as 505(b)(2).

There is a significant economic opportunity for IRX and the Company's shareholders, the first medical indications under investigation and Breakthrough Cancer Pain ('**BTcP**') and Panic Disorder ('**PD**'), both of which currently have limited safe and effective treatment options.

IRX holds an innovation patent and provisional patents for the nominated indications and the Company plans to continue to strengthen this position.



In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to the resolution put to members at the meeting, which were **decided on a Poll**.

	Resolution	Proxy Votes						Poll			Result
		For	Against	Open	Exclusions	Abstain	Total	For	Against	Abstain	Carried / Not Carried
Resolution 1	APPROVAL TO APPOINT INGENU CRO PTY LTD AS THE CONTRACT RESEARCH ORGANISATION, A RELATED PARTY OF THE COMPANY	30,317,147	20,000	-	51,775,715	-	30,337,147	30,317,147	20,000	-	Carried
		99.93%	0.07%	0.00%				99.93%	0.07%		